An emerging pharmaceutical manufacturer was preparing to launch its first commercial product, which would be the first new brand drug for a specific indication in 20 years. The client was looking for assistance with trade/distribution.
The Two Labs team developed and executed a full Commercialization strategy that included not just Product Launch, ASL and Trade Management, but also EHRx and Compendia, as we saw an opportunity to create a new drug classification for this product.
The Compendia team established a new classification for the drug and, based on their positive experience with Two Labs, the manufacturer continued working with Two Labs for EHRx, Compendia, and Trade Management services for another upcoming product launch.
A leading manufacturer in the cannabis space wanted to introduce a first in class cannabinoid treatment to be used for seizures.
Two Labs’ Compendia Team worked to develop the key components of the package insert, artwork files and dossier to shape the strategy and key clinical messages. We coordinated with internal stakeholders to ensure that the product messaging was in alignment with the Compendia data that is accessed by managed care organizations for reimbursement, EMRs for access and prescribing, as well as hospitals and key organizations that would treat patients who experience seizures.
We achieved success in taking a first in class cannabidiol product and reclassifying it as an anticonvulsant as a strategy to include the drug in the Compendia and introduce it to the market.
A specialty biopharmaceutical company was launching a new product into a competitive space and needed to expedite visibility into EHR platforms to reach their sales goals.
The Two Labs team deployed our iOS App model to their sales representatives to address the product visibility issues at the HCP level. The app assisted HCPs with system updates and manual additions, which expedited the electronic prescribing process. In addition, Two Labs provided the steps to set the new product as a favorite within the HCPs EHR system, differentiating it from competitors and streamlining the prescribing process.
The client saw a very successful early sales trajectory with over 3,000 HCPs prescribing the product to over 11,000 patients in the first two months. The ROI for our services was more than five times the investment, with only one third of the sales force actively submitting cases.
An emerging biotech company was preparing to launch its first product in the neurology space and, because they had an underdeveloped staff, needed help with pricing and managed care strategies.
Two Labs’ Market Access team developed a pricing and managed care strategy by analyzing the disease state using secondary data, researching analogues to optimize the launch, and combining payer, physician and patient research. The team also developed a strategy for if, how, and when to contact select payers.
Two Labs established a pricing strategy that maximized value and simplified access for the new drug. The team continues to support this client with managed care and payer strategies.
An established and well-known pharmaceutical manufacturer with multiple commercialized products in the market wanted to launch a new generic business entity within a tight timeline, making it difficult to achieve licensing on time.
Our PharmaLicense team developed a licensing strategy to add the generic entity as a DBA/trade name to the client’s current licenses. Two Labs engaged directly with state regulators in a timely fashion to identify and file the necessary documentation and mitigate any concerns.
By deploying the DBA/tradename strategy, PharmaLicense eliminated 9-12 months of licensing workstream, allowing the client to push their generic launch forward, creating millions in incremental revenue. We later deployed the same strategy with similar success and benefits for another newly created branded entity under the same umbrella company.
An emerging pharma company was launching two products and they needed help developing a comprehensive path to help them get from clinical to commercial.
Two Labs partnered with the company and supported them with our entire suite of services: Channel Strategy and Implementation, Compendia, EHRx, Trade, and Licensing.
The manufacturer and its new drugs overperformed against market expectations, with sales today in excess of $700 million. Two Labs has been asked to continue to partner with them over the course of seven years.
A leading manufacturer of dermatology products was going through a product acquisition and during the transition was concerned with inventory being correctly accounted for according to the terms agreed upon by all parties in the acquisition.
The Two Labs Trade team utilized our unique understanding of channel data to find $4 million of inventory that was not being accounted for, the liabilities of which should have been the responsibility of the large multi-national pharma company who was selling the product. The situation required a deep understanding of trade, distribution, finance and data. It was necessary for us to show where the error was made and how it was overlooked.
The inventory which Two Labs ‘found’ was determined to be the financial responsibility of the selling company. This discovery saved the client dollars on every unit, in terms of reduced liability costs.